BiondVax CEO to Present Universal Flu Vaccine Technology at BIO International Convention

NESS ZIONA, Israel, June 2, 2016

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be presenting and participating in a panel discussion at BIO International Convention in San Francisco.

The session, titled "Solving the Flu Problem: Can New Technologies Lead to Universal Flu Vaccines?" will be held on Tuesday, June 7 at 1:00pm in the Moscone Center, room West 3004.

Dr. Babecoff will discuss the technology and promising clinical trial results of M-001, BiondVax's universal flu vaccine candidate. Also participating in the panel moderated by the US Biomedical Advanced Research and Development Authority (BARDA) will be representatives from FluGen and Janssen Pharmaceuticals.

Accompanying Dr. Babecoff will be Dr. Tamar Ben-Yedidia, BiondVax's Chief Science Officer. Those wishing to meet with Drs. Babecoff and Ben-Yedidia are invited to contact BiondVax's Business Development team.

About BiondVax Pharmaceuticals Ltd 
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit http://www.biondvax.com.

Forward Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.